Tanaka T, Satoh M, Yasunaga T, Horikawa R, Tanae A, Hibi I
Department of Endocrinology & Metabolism, National Children's Medical Research Center, Tokyo, Japan.
J Pediatr Endocrinol Metab. 1997 Nov-Dec;10(6):623-8. doi: 10.1515/jpem.1997.10.6.623.
It is well known that height at the onset of puberty is closely related to final height. To improve final height of short children who enter puberty at short stature, twenty-one short boys and six short girls were treated with a combination of GH and GnRH analog. The boys started the combination treatment at a mean age of 12.0 years when their mean height was 128.5 cm (-2.74 SD) and the girls at a mean age of 10.68 years when their mean height was 126.4 cm (-2.23 SD). The boys discontinued GnRH at a mean age of 16.88 years after a mean treatment period of 4.89 years when their height was 153.7 cm (-2.75 SD), and the girls at a mean age of 13.89 years after a mean treatment period of 3.20 years when their height was 143.3 cm (-1.94 SD). Bone age maturation significantly decelerated during the combination treatment. Bone age rarely exceeded 14 years in boys and did not exceed 13 years in girls. Bone age maturation during combination treatment decelerated after bone age 12 years in boys and 10.5 years in girls. On average, bone age matured at a mean rate of 0.48 years a year in boys and 0.56 years a year in girls during the combination treatment. During the combination treatment, height velocity did not decelerate rapidly and remained at 3-5 cm/year for a longer duration because of the bone age deceleration, although a definite pubertal growth spurt was not observed. As a consequence, the mean projected height SDS for bone age increased 1.50 (+/- 0.76) SD in boys and 1.24 (+/- 0.49) SD during the combination treatment. Although most of the patients have not yet reached their final height, combined GnRH analog and GH treatment should increase the pubertal height gain and the adult height in short children who enter puberty early for height, when the post-GST growth is taken into account. The combination treatment seems more effective in boys than in girls. This improvement is attributed to the lengthening of the treatment period by slower bone maturation and maintained growth velocity.
众所周知,青春期开始时的身高与最终身高密切相关。为了提高身材矮小且青春期开始时身材就矮小的儿童的最终身高,对21名矮小男孩和6名矮小女童采用生长激素(GH)和促性腺激素释放激素(GnRH)类似物联合治疗。男孩开始联合治疗的平均年龄为12.0岁,此时他们的平均身高为128.5厘米(-2.74标准差);女孩开始联合治疗的平均年龄为10.68岁,此时她们的平均身高为126.4厘米(-2.23标准差)。男孩在平均治疗4.89年后,于平均年龄16.88岁停止使用GnRH,此时他们的身高为153.7厘米(-2.75标准差);女孩在平均治疗3.20年后,于平均年龄13.89岁停止使用GnRH,此时她们的身高为143.3厘米(-1.94标准差)。联合治疗期间骨龄成熟显著减缓。男孩骨龄很少超过14岁,女孩骨龄不超过13岁。联合治疗期间,男孩骨龄在12岁、女孩骨龄在10.5岁之后骨龄成熟减缓。联合治疗期间,男孩骨龄平均每年成熟0.48岁,女孩平均每年成熟0.56岁。联合治疗期间,由于骨龄减缓,身高增长速度没有迅速减慢,而是在较长时间内保持在3 - 5厘米/年,尽管未观察到明确的青春期生长突增。结果,联合治疗期间男孩骨龄预测身高标准差评分平均增加1.50(±0.76)标准差,女孩增加1.24(±0.49)标准差。尽管大多数患者尚未达到最终身高,但考虑到生长激素治疗后(GST)的生长情况,GnRH类似物和GH联合治疗应能增加身材矮小且青春期开始较早儿童的青春期身高增长和成人身高。联合治疗对男孩似乎比对女孩更有效。这种改善归因于骨成熟减缓延长了治疗期并维持了生长速度。